<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle><![CDATA[STTR Phase I:  Development of an Intranasal Vaccine for COVID-19]]></AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>10/01/2020</AwardEffectiveDate>
<AwardExpirationDate>03/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>276000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>15030000</Code>
<Directorate>
<Abbreviation>TIP</Abbreviation>
<LongName>Dir for Tech, Innovation, &amp; Partnerships</LongName>
</Directorate>
<Division>
<Abbreviation>TI</Abbreviation>
<LongName>Translational Impacts</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI/>
<PO_PHON/>
</ProgramOfficer>
<AbstractNarration><![CDATA[The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is development of a novel, safe and effective, non-invasive, vaccine for the COVID-19 pandemic.  Currently there is no approved vaccine for SARS-CoV-2, and some candidates are administered intramuscularly. The proposed intranasal vaccine directly interacts with the respiratory tract and may provide improved protection and virus clearance. The proposed vaccine is non-invasive, easy to administer, and may be effective in a single dose, thus impacting future social distancing needs. &lt;br/&gt;&lt;br/&gt;This Small Business Technology Transfer (STTR) Phase I project will develop an intranasal coronavirus vaccine and determine the most promising formulation, with tasks including: 1) synthesis of novel coronavirus antigens and formulation of intranasal vaccine using liposome nanoparticles, including antigen discovery, liposome nanoparticle formulation, and in vitro characterization; 2) preclinical testing of intranasal coronavirus vaccine in an animal model, including intranasal vaccination, serum antibody analysis, virus challenge and analysis of protection efficacy. The outcome of this Phase I study is to obtain an optimized nanoparticle intranasal vaccine formulation for induction of robust T and B cell responses specific to SARS-CoV-2 S and N protein.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.]]></AbstractNarration>
<MinAmdLetterDate>09/22/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/16/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2032325</AwardID>
<Investigator>
<FirstName>Maoqi</FirstName>
<LastName>Feng</LastName>
<PI_MID_INIT>M</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Maoqi M Feng</PI_FULL_NAME>
<EmailAddress><![CDATA[contact@polykalatech.com]]></EmailAddress>
<NSF_ID>000783165</NSF_ID>
<StartDate>01/05/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Xingguo</FirstName>
<LastName>Cheng</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Xingguo Cheng</PI_FULL_NAME>
<EmailAddress><![CDATA[Xchengswri@gmail.com]]></EmailAddress>
<NSF_ID>000794063</NSF_ID>
<StartDate>09/22/2020</StartDate>
<EndDate>01/05/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Renukaradhya</FirstName>
<LastName>Gourapura</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Renukaradhya Gourapura</PI_FULL_NAME>
<EmailAddress><![CDATA[gourapura.1@osu.edu]]></EmailAddress>
<NSF_ID>000826339</NSF_ID>
<StartDate>09/22/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>DYNAMIC ENTROPY TECHNOLOGY, LLC</Name>
<CityName>PASCO</CityName>
<ZipCode>993015216</ZipCode>
<PhoneNumber>2102484440</PhoneNumber>
<StreetAddress>1028 W NIXON ST</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Washington</StateName>
<StateCode>WA</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>WA04</CONGRESS_DISTRICT_ORG>
<ORG_UEI_NUM>KRP2M1FKAG54</ORG_UEI_NUM>
<ORG_LGL_BUS_NAME>DYNAMIC ENTROPY TECHNOLOGY, LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_UEI_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[DYNAMIC ENTROPY TECHNOLOGY, LLC]]></Name>
<CityName>Devine</CityName>
<StateCode>TX</StateCode>
<ZipCode>780165145</ZipCode>
<StreetAddress><![CDATA[196 County Rd 7611]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>TX23</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramElement>
<Code>8091</Code>
<Text>SBIR Outreach &amp; Tech. Assist</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<ProgramReference>
<Code>8042</Code>
<Text>Health and Safety</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Fund>
<Code>01002021DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<Fund>
<Code>01002122DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<FUND_OBLG>2020~256000</FUND_OBLG>
<FUND_OBLG>2021~20000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>The spread of severe acute respiratory syndrome coronavirus&nbsp;2 (SARS-CoV-2) which causes COVID-19 has resulted in extensive social and economic impacts worldwide. In contrast to current COVID-19 intramuscular vaccines, apotent vaccine delivered intranasal reaching the respiratory tract, the primary site of infection and disease has additional benefits. Intranasal nanoparticle vaccines have been shown to induce long-lasting mucosal and systemic cross-protective immunity. Therefore, development of a safe, potent, broadly protective, and importantly non-invasive intranasal vaccine to fight against COVID-19 and its emerging variants is warranted. In this NSF Phase I STTR funded project, we developed an intranasal deliverable liposome nanoparticle-based SARS-CoV-2 vaccine, containing nucleocapsid (N) and spike receptor binding domain (S-RBD) antigens delivered either as subunit proteins or mRNA along with an adjuvant encapsulated in liposome with over 95%. Our data demonstrated the superior efficiency of our novel candidate SARS-CoV-2 subunit proteins (S-RBD and N) based vaccine against the challenge infection in ferrets, supported by reduced viral load in the respiratory tract and strongly induced local mucosal immune responses. The success of our preclinical study in the ferret model has provided scope for further investigation towards developing a noninvasive and promising prophylactic cost-effective and easily applied intranasal vaccine candidate against circulating and emerging SARS-CoV-2 mutants.</p> <p>&nbsp;</p><br> <p>            Last Modified: 04/30/2022<br>      Modified by: Maoqi&nbsp;M&nbsp;Feng</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 has resulted in extensive social and economic impacts worldwide. In contrast to current COVID-19 intramuscular vaccines, apotent vaccine delivered intranasal reaching the respiratory tract, the primary site of infection and disease has additional benefits. Intranasal nanoparticle vaccines have been shown to induce long-lasting mucosal and systemic cross-protective immunity. Therefore, development of a safe, potent, broadly protective, and importantly non-invasive intranasal vaccine to fight against COVID-19 and its emerging variants is warranted. In this NSF Phase I STTR funded project, we developed an intranasal deliverable liposome nanoparticle-based SARS-CoV-2 vaccine, containing nucleocapsid (N) and spike receptor binding domain (S-RBD) antigens delivered either as subunit proteins or mRNA along with an adjuvant encapsulated in liposome with over 95%. Our data demonstrated the superior efficiency of our novel candidate SARS-CoV-2 subunit proteins (S-RBD and N) based vaccine against the challenge infection in ferrets, supported by reduced viral load in the respiratory tract and strongly induced local mucosal immune responses. The success of our preclinical study in the ferret model has provided scope for further investigation towards developing a noninvasive and promising prophylactic cost-effective and easily applied intranasal vaccine candidate against circulating and emerging SARS-CoV-2 mutants.          Last Modified: 04/30/2022       Submitted by: Maoqi M Feng]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
